surmount-1 tirzepatide Lilly Shows Superiority in SURMOUNT-3 and 4 Lilly and Company's SURMOUNT-1 study

[4] Participants in this study also made diet and exercise changes alongside taking tirzepatide

Third, the follow-up duration in most included trials was limited to 72 weeks or less

Glucagon-like peptide-1 (GLP-1)-based therapies improve all these variables but whether the dual GLP-1 / glucose-dependent insulinotropic polypeptide (GIP) agonist tirzepatide is superior to semaglutide in attaining therapeutic targets remains unclear

Results: Across completed head-to-head randomized trials, tirzepatide consistently achieved greater reductions in body weight, and HbA1c than semaglutide in individuals with obesity or T2DM

[1] [2] If a patient needs to change their injection day, the FDA label permits this as long as the new dose is administered at least 72 hours (three days) after the previous injection